Presented preclinical data showing azenosertib combinations induced complete tumor responses in ADC-resistant triple-negative breast cancer (TNBC) models. Demonstrated that azenosertib monotherapy achieved 42-99% tumor growth inhibition across 12 diverse TNBC in vivo models. Showed that azenosertib combined with enfortumab vedotin (EV) induced complete responses in 87.5% of mice in an ADC-resistant TNBC model. Released real-world data confirming that Cyclin E1-positive ovarian cancer patients experience significantly worse clinical outcomes compared to Cyclin E1-negative patients. Reinforced the strategic focus on azenosertib as a biomarker-driven treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC).